Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Imvotamab · IGM-2323

Bispecific antibody · Kills target cells, directed at CD20 (MS4A1) and CD3 (CD3E) · developed by IGM Biosciences

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is Imvotamab?

Imvotamab is an engineered IgM bispecific antibody with ten binding domains for CD20 and one for CD3. It cross-links T cells to CD20-expressing B-cell lymphomas, triggering cytotoxic T-cell responses and complement-dependent cytotoxicity. It is studied in relapsed/refractory B-cell non-Hodgkin lymphomas including follicular lymphoma, DLBCL, and mantle cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IGM-2323
Drug type
Bispecific antibody
Targets
CD20 (MS4A1), CD3 (CD3E)
Mechanism
Kills target cells, directed at CD20 (MS4A1) and CD3 (CD3E)
Pathways
complement-dependent cytotoxicity, T-cell activation
Therapy area
Oncology
Developer
IGM Biosciences, Inc.
In trials of
ADCT
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
F3HG38I0T1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04082936 Phase 1/2 Non-Hodgkin Lymphoma Terminated ADCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

DLBCLFollicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaNon-Hodgkin Lymphoma

Other drugs acting on MS4A1 / CD3E

Anti-Thymocyte Globulin FDA approved Blinatumomab FDA approved AZD5492 Phase 1/2 CT-95 Phase 1 Foralumab Phase 2 Gocatamig Phase 1/2 Mipletamig Phase 1 MK-1045 Phase 2/3 Odronextamab Phase 2/3 TAK-186 Phase 1/2 TL011 Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.